Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study
Nucleic Acid Therapeutics · 01.04.2026 · 36 (2) · 100-108
DOI: 10.1177/21593337251405312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 22.12.2025. Verfasst von Emma T Groenwold und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, McGill University, Montreal, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Oligonucleotides, Antisense, Exons, Dystrophin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: U.S. Department of Defense, Natural Sciences and Engineering Research Council of Canada, Clinical Center.
Abstract (Originalsprache)
Exon skipping antisense oligonucleotides (AONs) have been extensively studied as a promising method of treating Duchenne muscular dystrophy (DMD), yet the clinical efficacy of the conditionally approved AONs still remains low. Using phosphorothioated locked nucleic acid/2′-fluoro-RNA AONs, we aimed to increase AON efficiency by employing skeletal muscle-targeting conjugate molecules, cholesterol, and docosanoic acid to improve the biodistribution of the therapeutic. While conjugate molecules were able to induce high levels of skipping in an in vitro model, in vivo studies in the hDMDdel52/ mdx mouse model caused adverse symptomatic and systemic immune reactions, up to and including death, with little to no appreciable increase in exon skipping. Our study cautions against using these AON conjugates in an animal model due to severe toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, McGill University, Montreal, Canada.
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts.
- Proefdiercentrum, Leiden University Medical Center, Leiden, the Netherlands.
- Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, Texas.
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
ORCID-Profile: Alicia Montulet
Förderung
- U.S. Department of Defense
- Natural Sciences and Engineering Research Council of Canada
- Clinical Center
Zitieren
APA
Groenwold, E. T., Montulet, A., Stan, T., van de Vijver, D., McCorquodale, D., McHugh, N., Echeverria, D., Winter, C. T., van de Wal, M., O'Reilly, D., Khvorova, A., Aartsma-Rus, A., & Damha, M. J. (2026). Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study. Nucleic Acid Therapeutics, 36(2), 100-108. https://doi.org/10.1177/21593337251405312
Vancouver
Groenwold ET, Montulet A, Stan T, van de Vijver D, McCorquodale D, McHugh N, et al. Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study. Nucleic Acid Therapeutics. 2026;36(2):100-108. doi:10.1177/21593337251405312
BibTeX
@article{Groenwold2026,
author = {Groenwold, Emma T and Montulet, Alicia and Stan, Tiberiu and van de Vijver, Davy and McCorquodale, Diana and McHugh, Nicholas and Echeverria, Dimas and Winter, Christa Tanganyika-de and van de Wal, Maarten and O'Reilly, Daniel and Khvorova, Anastasia and Aartsma-Rus, Annemieke and Damha, Masad J},
title = {Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study},
journal = {Nucleic Acid Therapeutics},
year = {2026},
volume = {36},
number = {2},
pages = {100--108},
doi = {10.1177/21593337251405312}
}
EUVIMED